Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/increase-in-overall-mortality-risk-in-patients-with-type-2-diabetes-LbyeyfTCBh
References (22)
-
F. Tomai, F. Crea, A. Gaspardone, F. Versaci, R. Paulis, Alfonso Peppo, L. Chiariello, P. Gioffrè (1994)
Ischemic Preconditioning During Coronary Angioplast Is Prevented by Glibenclamide, a Selective ATP‐Sensitive K+ Channel BlockerCirculation, 90
-
D. Flynn, Andrew Smith, J. Treadway, C. Levy, W. Soeller, W. Boettner, Peter Wisniecki, D. Plowchalk, S. Gernhardt, W. Tracey, D. Knight (2005)
The Sulfonylurea Glipizide Does Not Inhibit Ischemic Preconditioning in Anesthetized RabbitsCardiovascular Drugs and Therapy, 19
-
D'Agostino (1998)
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStat Med, 17
-
H. Horsdal, S. Johnsen, F. Søndergaard, J. Jacobsen, R. Thomsen, O. Schmitz, H. Sørensen, J. Rungby (2009)
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population‐based follow‐up studyDiabetes/Metabolism Research and Reviews, 25
-
R. Snee (1977)
Validation of Regression Models: Methods and ExamplesTechnometrics, 19
-
D. Nathan, J. Buse, M. Davidson, E. Ferrannini, R. Holman, R. Sherwin, B. Zinman (2008)
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapyDiabetologia, 52
-
Hoenig (2001)
The abuse of power: the pervasive fallacy of power calculations for data analysisAm Stat, 55
-
D. Nathan (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 32
-
Harald Klepzig, G. Kober, C. Matter, H. Luus, H. Schneider, K. Boedeker, W. Kiowski, F. Amann, D. Gruber, S. Harris, W. Burger (1999)
Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.European heart journal, 20 6
-
A. Gangji, T. Cukierman, H. Gerstein, C. Goldsmith, C. Clase (2007)
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular EventsDiabetes Care, 30
-
J. Schafer (1999)
Multiple imputation: a primerStatistical Methods in Medical Research, 8
-
H. Maddock, Sylvia Siedlecka, D. Yellon (2004)
Myocardial Protection from Either Ischaemic Preconditioning or Nicorandil Is Not Blocked by GliclazideCardiovascular Drugs and Therapy, 18
-
G. Heijden, A. Donders, T. Stijnen, K. Moons (2006)
Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example.Journal of clinical epidemiology, 59 10
-
J. Hoenig, Dennis Eisey (2001)
Statistical Practice The Abuse of Power: The Pervasive Fallacy of Power Calculations for Data Analysis -
C. Andersson, G. Gislason, C. Jørgensen, P. Hansen, A. Vaag, R. Sørensen, Charlotte Mérie, J. Olesen, P. Weeke, M. Schmiegelow, M. Norgaard, L. Køber, C. Torp-Pedersen (2011)
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.Diabetes research and clinical practice, 94 1
-
T. Schramm, G. Gislason, A. Vaag, J. Rasmussen, F. Folke, M. Hansen, E. Fosbøl, L. Køber, M. Norgaard, M. Madsen, P. Hansen, C. Torp-Pedersen (2011)
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.European heart journal, 32 15
-
K. Pantalone, M. Kattan, Changhong Yu, B. Wells, S. Arrigain, Anil Jain, A. Atreja, R. Zimmerman (2010)
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride MonotherapyDiabetes Care, 33
-
Schafer (1999)
Multiple imputation: a primerStat Methods Med Res, 8
-
M. Zeller, N. Danchin, D. Simon, A. Vahanian, L. Lorgis, Y. Cottin, J. Berland, P. Guéret, P. Wyart, R. Deturck, X. Tabone, J. Machecourt, F. Leclercq, E. Drouet, G. Mulak, V. Bataille, J. Cambou, J. Ferrières, T. Simon (2010)
Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.The Journal of clinical endocrinology and metabolism, 95 11
-
R. D'Agostino (2005)
Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group -
M. Khalangot, M. Tronko, V. Kravchenko, V. Kovtun (2009)
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.Diabetes research and clinical practice, 86 3
-
K. Pantalone, M. Kattan, Changhong Yu, B. Wells, S. Arrigain, Anil Jain, A. Atreja, R. Zimmerman (2009)
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysisActa Diabetologica, 46
- Publisher
- Wiley
- Copyright
- © 2012 Blackwell Publishing Ltd
- ISSN
- 1462-8902
- eISSN
- 1463-1326
- DOI
- 10.1111/j.1463-1326.2012.01604.x
- pmid
- 22486923
- Publisher site
- See Article on Publisher Site
Abstract
Aims: It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in a large cohort of patients with type 2 diabetes.
Journal
Diabetes Obesity & Metabolism – Wiley
Published: Sep 1, 2012
Keywords: ; ; ; ;